The purpose of this study is to assess the safety of the investigational drug DLYE5953A at different dose levels in patients with advanced solid tumors that have continued to grow despite at least one prior regimen of therapy. DLYE5953A is a combination of an antibody and an anticancer drug. The antibody targets a protein on some cancer cells called Ly6E. It is designed to bind to cancer cells containing this protein and then release the anticancer drug, which kills the cancer cell.
Laboratory studies have shown that DLYE5953A can kill cancer cells, slow the growth of cancers, and shrink tumors. DLYE5953A is given intravenously (by vein).